x

RSS Newsfeeds

See all RSS Newsfeeds

Global Regions

Global Regions ( XML Feed )
United States ( XML Feed )

Feb 9, 2016 3:47 EST

Orion Biopharmaceuticals: A new, therapeutic approach for the treatment of auto-immune diseases through specific interaction with the immune cells responsible for disease progression

iCrowdNewswire - Feb 9, 2016

Orion Biopharmaceuticals

Orion Biopharmaceuticals Logo

Orion Biopharmaceuticals is developing a new, therapeutic approach for the treatment of auto-immune diseases through specific interaction with the immune cells responsible for disease progression.

Products / Services

SAgA

Orion Biopharmaceuticals has developed a therapeutic technology for the treatment of autoimmune diseases, specifically Relapse-Remitting Multiple Sclerosis, through the use of a peptide-polymer conjugate identified as Soluble Antigen Array (SAgA).

Management

Chief Science/Scientist
Joshua Sestak

Leonard, A.K., Sestak, J.O., Costantino, H.R., Sileno, A.P., Peddakota, L.R., Sharghi, K.E., Bellamy, G.M., Gesty, J.P., (2009), “INTRANASAL CARBETOCIN FORMULATIONS AND METHODS FOR THE TREATMENT OF AUTISM,” U.S. Patent Application 20100311655.

Quay, S.C., …, Sestak, J.O., (2008), “Pharmaceutical Formation For
Increased Epithelial Permeability of Glucose-Regulating Peptide,” U.S. Patent Application 20080318837

Quay, S.C, …., Sestak, J.O., (2007), “COMPOSITIONS AND METHODS FOR THE TREATMENT OF PSYCHIATRIC DISORDERS,” U.S. Patent Application 20070032410.

1st Prize Research Poster Presentation at the Global Pharmaceutical Education Network (GPEN) Conference November 2010

2011 Recipient of The University of Kansas Graduate Research Presentation Award

Amgen Graduate Travelship for 2011 American Association of Pharmaceutical Scientists National Biotechnology Conference

1st Place Institute for Advancing Medical Innovation Venture Pitch Competition, July 2011

Contact Information:

Chief Science/Scientist
Joshua Sestak

Emmanuel Emeni

View Related News >
support